Objective: Extracorporeal membrane oxygenation (ECMO) is a widely used technique for treating postcardiotomy cardiogenic shock (PCS); however, no study has compared the long-term outcomes of patients who receive ECMO support for PCS with those of the general population post cardiac surgery.
See Editorial Commentary page 478.
Approximately 1% of adult patients who undergo cardiac surgery develop profound postcardiotomy cardiogenic shock (PCS) and require temporary mechanical circulatory support (MCS). 1 Extracorporeal membrane oxygenation (ECMO), because of its easy and rapid applicability, is widely used for MCS; the technique can facilitate myocardial function recovery and serve as a bridge to further therapy. [2] [3] [4] ECMO, which may constitute the last line of therapy for critically ill patients viewed as unlikely to survive without prompt MCS, has been reported as bringing positive outcomes in selected patients. [5] [6] [7] [8] [9] However, ECMO support after cardiac surgery carries a high mortality rate of 40% to 80%, 1, 6, 10, 11 and severe morbidity risks, particularly bleeding and thromboembolic complications. 12 Furthermore, a paucity of data on the long-term follow-up and detailed outcomes of ECMO for PCS raises concern regarding unwarranted use of ECMO and futile medical treatment.
In Taiwan, the use of ECMO for PCS is recommended, and the associated medical expenditure is reimbursed under the National Health Insurance (NHI) program. Therefore, ECMO is liberally used for PCS support without consideration of the financial costs. Thus, most patients in Taiwan who experience PCS receive ECMO support. Many retrospective and observational studies have demonstrated that the use of ECMO in Taiwan is effective. 2, 8, [13] [14] [15] Nearly the entire population of Taiwan has been covered by the NHI program since 1995; thus, the NHI claims database provides a unique platform for the detailed review and long-term follow-up of patients after they receive ECMO support. 16 No previous study has reported the relative outcomes of patients who receive ECMO support for PCS compared with the general population post cardiac surgery without PCS by using a nationwide database. Therefore, we conducted a population-based cohort study to investigate the mortality, complications, readmissions, and medical expenditure of patients who received ECMO support for PCS compared with a matched cohort during a 12-year period in Taiwan.
MATERIALS AND METHODS Data Source
This study was performed using data collected under the governmentoperated single-payer NHI program, which was launched in 1995 and covered nearly all (99%) of the approximately 23 million residents of Taiwan as of December 2015. 17 The National Health Insurance Research Database (NHIRD) is derived from the NHI program, which reimburses the costs of all lifesaving procedures, surgeries, and medication, including cardiac surgery.
Study Population
This was an open, observational, longitudinal cohort study comparing the outcomes of patients who did and did not receive ECMO support after cardiac surgery. We defined cardiac surgery as either a coronary artery bypass grafting (CABG) or valve surgery, the 2 most common types of heart surgery. We examined the NHIRD hospitalization records of all patients admitted for cardiac surgery between January 2000 and December 2011. The patients were identified according to the presence of an NHI procedure code for valve repair or replacement (68,015, 68,016, 68,017, and 68,018) or for CABG (68,023, 68,024, and 68,025). In total, 68,186 patients who underwent either surgery during the study period in Taiwan were identified. Patients were excluded if they were younger than 18 years or had missing demographic or surgical information. Patients with repeat hospitalizations for cardiac surgery and concomitant aortic surgery during the index hospitalization also were excluded. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) procedure code 39.65 was used to extract patients who received ECMO. The database does not permit definitive knowledge of the exact timing of ECMO implantation during index admission; however, we presumed that if a patient underwent ECMO and cardiac surgery during the same admission, most ECMO implantation occurred after cardiac surgery. Moreover, we validated the study design by using our own hospital database and, according to our study design, only 1.9% of ECMO took place before cardiac surgery. This was thus a rare occurrence that accounted for a small percentage of instances and was unlikely to affect our result.
Comorbidities and Outcomes
For all patients, we obtained inpatient records for at least 3 years before the index admission to track their history of comorbidities. For example, we enrolled patients in 2000 and identified comorbidities from their medical records since 1997. The hospitalization records from this period were used to identify preoperative comorbidities. The baseline characteristics and surgical details of the patients were identified using ICD-9-CM and NHI procedure codes for the index hospitalization and prior hospitalizations (Table E1 ). The accuracy of the ICD-9-CM, NHI procedure codes, and identification of the comorbidities of NHIRD has been validated in patients with cardiovascular disease and cardiac surgery; the NHIRD appears to be a valid resource for population research. 18, 19 The outcomes of interest in this study included ECMOrelated complications, all-cause mortality, first readmission and cumulative readmissions for any cause, and medical expenditure of admission. Withdrawal from the NHI program was used to identify mortality. 20 Inhospital expenditure was directly collected from the NHIRD. The date on which a patient was admitted for cardiac surgery was defined as the index hospitalization. The patients were followed from their index admission to December 31, 2011, or death; no missing data were found during the follow-up period in the database.
Propensity Score Matching
The retrospective study design did not allow the random allocation of the patients; this might raise a concern of selection bias. Therefore, we performed propensity score matching to compare patients who received ECMO with those who did not receive ECMO. 21 Each patient who received ECMO was matched with 5 patients who did not receive ECMO by using propensity scores according to age, sex, comorbidities, Charlson comorbidity index (CCI), hospital level (Table 1) , surgical characteristics (Table 2) , and index admission year. We adopted the greedy nearest neighbor matching algorithm and set the maximum tolerance level as 0.2 times the standard deviation of the propensity score (briefly, caliper ¼ 0.2) to guarantee the matching quality. An absolute standardized difference of less than 0.1 after matching was considered to indicate well-balanced matching variables between the groups. 22 Finally, 1141 patients who received ECMO were included before matching, and 4 of them were excluded after matching, yielding Figure 1 ).
Statistical Analysis
We compared the clinical and surgical characteristics of the ECMO and non-ECMO groups by using the c 2 and t tests for categorical and continuous variables (eg, age), respectively. The risks of in-hospital complications and outcomes between the study groups after matching were compared by using a univariate logistic regression model in which study group was the only covariate. Continuous outcomes (ie, intensive care unit [ICU] days, hospital stays, and inpatient medical expenditure) in the ECMO and non-ECMO groups after matching were compared by using a Mann-Whitney U test. We performed multivariable logistic regression analysis to evaluate the association of post-ECMO complications with the risk of in-hospital mortality. We adjusted for all the covariates listed in Table 1 and surgical type, and the 7 post-ECMO complications (eg, ischemic stroke and acute renal failure) were introduced into the multivariable logistic model simultaneously. To compare the risk of all-cause mortality between the study groups, we constructed survival curves by using the Kaplan-Meier method in addition to the log rank test. For conducting comparisons among the groups with regard to time-to-event outcomes other than mortality (eg, first readmission for any cause), we performed competing risk survival analysis, in which mortality was considered a competing risk. 23 With respect to comparing the mean number of hospitalizations between the groups, we applied the generalized linear mixed model in which the Poisson distribution was set and the logarithm of follow-up duration was treated as an offset variable; moreover, the effect of multiple events involving a patient was considered in the model. We stratified the patients in the ECMO group by age, CCI, and surgery type and then constructed Kaplan-Meier survival curves of all-cause mortality along with the log rank test to compare differences. In addition, risk factors of 1-year mortality in the ECMO group were investigated by using a multivariable Cox proportional hazard model in which all the variables listed in Table 1 and surgical type were treated as covariates. Medical expenditure (cost for all subsequent hospital admissions) after the index admission discharge were compared between the study groups by using the MannWhitney U test. The medical expenditures from 2000 to 2010 were normalized to 2011 according to the consumer price index of Taiwan. All data analyses were conducted by using SPSS 22 (IBM Corp, Armonk, NY). Table 1 shows the baseline demographics and comorbidities of both study groups. We identified 1141 patients who received ECMO support for PCS between 2000 and 2011 and who met the inclusion criteria. These patients had a mean age of 63.8 AE 13.2 years, and 71.3% of them were men. The incidence of ECMO use after cardiac surgery was 1.91%. Table 2 presents the cardiac surgery history of the study groups before and after propensity score matching. After matching, the absolute standardized difference of each variable was less than 0.1, indicating the distribution of matching variables was well-balanced between groups.
RESULTS

Study Population Characteristics
In-Hospital Mortality and Postoperative Complications
The ECMO group had a significantly higher risk of inhospital mortality than did the non-ECMO group (61.7% vs 6.8%, odds ratio 22.34, 95% confidence interval [CI] 19.06-26.18). The ECMO group also had a higher risk of postoperative complications than did the non-ECMO group, including reexploration for bleeding, massive blood transfusion with more than 8 units of packed red blood cells, new-onset hemorrhagic stroke, acute renal failure requiring hemodialysis, postoperative infection, leg ischemia requiring fasciotomy or amputation and intra-aortic balloon pump (IABP) support. In addition, the inpatient medical expenditure of the ECMO group was approximately twice that of the non-ECMO group (median: 76.7 vs 38.5 New Taiwan Dollar [NTD] 3 10 4 , P<.001). In addition, the patients in the ECMO group had longer ICU durations, but slightly shorter hospital stays (Table 3 ).
In addition, the following variables were found be associated with a higher chance of survival during the index admission in the ECMO group: a younger age, presence of hypertension, absence of heart failure, and absence of liver cirrhosis (Table E2 ). Figure 2 , A and B, illustrate the Kaplan-Meier survival curves for all-cause mortality and first readmission for any cause, respectively. The results revealed that the risk of all-cause mortality was greater in the ECMO group than in the non-ECMO group (P <.001) in the first year of follow-up, whereas no difference was observed after the first year of follow-up (P ¼ .209; Figure 2, A) . Similar results were observed regarding first readmission for any cause (Figure 2, B) . We also observed a greater mean number of readmissions for any cause during the follow-up in the ECMO group (mean, 0.68; 95% CI, 0.60-0.78) than in the non-ECMO group (mean, 0.52; 95% CI, 0.50-0.55) and this group difference was statistically significant (rate ratio [RR] 1.31; 95% CI, 1.13-1.50; Figure 2 , C). Figure 3 presents the medical expenditure (cost for all subsequent hospital admissions) after index admission discharge. This analysis included those patients who were followed and survived beyond the specific follow-up period (ie, the first year). The results revealed that medical expenditure was greater for the ECMO group than for the non- 
ECMO group during the first year of follow-up (P <.001).
No difference between groups was observed from the second year of follow-up onward. In addition, the following variables were found be associated with a higher chance of survival during the first year of follow-up in the ECMO group: a younger age, absence of heart failure, and absence of chronic kidney disease or dialysis (Table E3) . Figure 4 summarizes the results regarding the effects of ECMO-related complications on in-hospital mortality. The results indicated that among the most common ECMO-related complications, acute renal failure requiring hemodialysis (OR 1.94; 95% CI, 1.45-2.59) and massive blood transfusion with more than 8 units of packed red blood cells (OR 1.58; 95% CI, 1.15-2.17) were associated with a higher risk of in-hospital mortality.
Effect of ECMO-Related Complications on InHospital Mortality
Associations of Age, Comorbidity, and Surgery Type With Mortality Figure E1 , A to C, shows the Kaplan-Meier survival curves for identifying the correlation of mortality with age, CCI score, and surgery type. The results indicated that an older age and a higher CCI score were associated with a higher all-cause mortality rate (both P for linear trend of log rank test < .001). Furthermore, the patients who received both CABG and valve surgery had a higher risk of mortality during follow-up than did those who received CABG alone or valve surgery alone (both P of log rank test < .05).
DISCUSSION
In this study, we compared 1137 patients who received ECMO after cardiac surgery in a 12-year period with a matched control group by using a nationwide Taiwan database. The incidence of ECMO use for treating PCS was 1.91%, with an in-hospital mortality rate of 61.6%. To our knowledge, this is the largest cohort study of ECMO for PCS. In Taiwan, the NHI sets uniform indications regulated by Taiwan NHI administration for use of ECMO. Furthermore, this is the first study to compare the long-term outcomes of patients who received ECMO support for PCS with those of a matched control group. By doing so, we demonstrated the favorable long-term outcomes after the first year of follow-up for critically ill patients who presumably would not have survived without receiving prompt MCS.
The major findings of this research support the argument that ECMO might provide a favorable late prognosis for patients with PCS. The causes of PCS are complex; in addition to critical preoperative conditions and comorbidities, intraoperative disaster events also contribute to the development of PCS. 5 Tarzia et al 24 demostrated that ECMO alone is associated with a considerable likelihood of recovery from cardiogenic shock with an acute etiology, but not from that with a chronic etiology. The subgroup analysis in our study showed that an older age, advanced preoperative comorbidities, and complex surgery were all related to chronic etiology-associated poor long-term outcomes in the ECMO group. Our results also suggested that ECMO might provide a survival benefit only for patients who experience an intraoperative event and who are in a relatively healthy preoperative condition. Combes et al 25 showed that most patients receiving ECMO discharged from ICU could survive at 1 year, and a quality-of-life survey demonstrated a trend toward normalization of quality of life over time after hospitalization. Anselmi et al 26 demonstrated that patients who survive acute events as a result of ECMO for cardiopulmonary resuscitation may attain similar health-related quality of life compared with similar populations of critical care patients. Furthermore, the cardiac-RESCUE program of Beurtheret et al 27 yielded favorable long-term functional outcomes after ECMO support for refractory cardiogenic shock. Among the patients who received this treatment and were subsequently discharged, the 1-year survival rate was 93.8%, with a New York Heart Association heart failure class of 1.5 AE 0.6 during follow-up. However, further investigation in the form of prospective randomized multicenter studies is required to establish how and with whom ECMO should be used. The use of ECMO for PCS is a lifesaving procedure; however, the literature reports considerable associated morbidity following this intervention, 12 particularly bleeding and thromboembolism-related complications. Data from this study, which compared an ECMO group with a matched control group, support this notion. No previous study has demonstrated which ECMO-related complications are associated with mortality. We found that massive blood transfusion and acute renal failure are associated with in-hospital mortality. Acute kidney injury requiring renal replacement therapy during ECMO support is associated with poor outcomes. 13, 28, 29 Excessive accumulated extravascular water impairs oxygen transport in tissue and is associated with subsequent organ dysfunction. ECMO is associated with bleeding complications and typically requires large blood transfusions. A larger number of transfused red blood cell units is well known to be associated with increased mortality after cardiac surgery, 30 and this relationship may extend to patients receiving ECMO. 31 Our study suggests that meticulous hemostasis for avoiding unnecessary bleeding, a restrictive strategy of blood transfusion, and an aggressive renal protective strategy may improve the outcomes of ECMO support for PCS.
Study Strengths
This study has several strengths. First, the current related literature has a paucity of large randomized trials and is Table 1 and surgical type in Table 2 and the 7 complications were introduced into the model simultaneously. CI, Confidence interval.
limited by small sample sizes, single-outcome investigations, and a lack of control groups. We conducted a national observational study of ECMO for PCS and compared outcomes with a non-ECMO group through propensity score matching. The sample size was the largest of any study on this topic, providing adequate statistical power for analyzing variable outcomes. Second, the NHIRD provides a unique platform for the detailed evaluation of outcomes seldom investigated previously, such as readmission and medical expenditure, and enables complete long-term follow-up with limited missing data. Finally, the NHI program covers nearly all Taiwan residents, and ECMO is the only advanced MCS technique covered by the program. Thus, the universal coverage of expensive and advanced ECMO devices reduces socioeconomic or residential location barriers that may have otherwise caused selection bias.
Study Limitations
Some study limitations should be noted. First, the incidence of ECMO treatment for PCS was relatively high (1.91%). It may be due to delayed referral for cardiac surgery and poor preoperative myocardial function being common in Taiwan; these factors may contribute to a higher incidence of PCS. Furthermore, the use of ECMO for PCS is reimbursed under the Taiwan NHI. Therefore, ECMO is liberally used for PCS treatment without consideration of the financial costs, and nearly all patients who experienced severe PCS received ECMO support. However, the NHI program has strict regulations regarding ECMO reimbursements, which are granted only to patients who have clinical or examination evidence of profound PCS. Furthermore, terminal chronic diseases, such as irreversible brain damage, are contraindicated for reimbursement. The second limitation is the relatively high mortality of the control group, which reflects real-world data outside developed Western countries. The low medical expenditure for admissions in Taiwan (approximately 10% of the costs in the United States) may have negatively affected the outcomes of cardiac surgery. Third, the NHIRD did not include data regarding information such as the ventricular ejection fraction, which is the most powerful predictor of mortality in this population, and other ECMO-related parameters, such as cannula size, insertion (central or peripheral), supporting duration, whether mortality occurred on ECMO or after ECMO removal, laboratory data, or other detailed clinical information reflecting the severity of patients on ECMO implantation, and whether adequate perfusion was achieved. However, we adopted alternative variables as proxies for unavailable information, such as congestive heart failure, which is associated with the left ventricular ejection fraction. Other ECMO parameters are relatively less predictive of long-term outcomes. Finally, the data we claimed included only all inpatient costs. The medical expenditure of the outpatient department was not available in our study. Underestimation of the financial burden by limiting the analysis to hospital expenses only should be noted and evaluated. Despite these limitations, we believe that the strengths of our study provide a valuable contribution to outcome analysis in patients with ECMO for PCS.
CONCLUSIONS
Compared with the non-ECMO group, the ECMO group had significantly poorer outcomes during the first year of follow-up. However, the all-cause mortality, readmission for any cause, and medical expenditure of the groups did not differ significantly after 1 year of follow-up. We concluded that ECMO support for PCS might yield favorable long-term outcomes (Video 1).
Among the patients who received ECMO support for PCS, we observed that ECMO-associated complications of acute renal failure and massive blood transfusion were risk factors for in-hospital mortality. An older age, advanced preoperative comorbidities, and surgical complexity were associated with long-term mortality. Our study suggests that ECMO might provide a survival benefit only for patients who experience an intraoperative event and who are in a relatively healthy preoperative condition.
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